CORESTA In vitro Toxicology Task Force. In vitro exposure of cells to Smoke at the Air Liquid Interface

Similar documents
TNCO Testing procedures

The Effect of Puff Duration on Smoke Chemistry

Ian M. Fearon, Madeleine Ashley, Christopher J. Shepperd, Graham Errington. Sheri A. Bowman, John W. Caraway, Peter Chen, Paul R.

The Effect of Puff Profile and Volume on the Yields of E-Cigarettes

CORESTA Recommended Method No. 78

Particle Size Distribution of E-Cigarette Aerosols and the Relationship to Cambridge Filter Pad Collection Efficiency

Next Generation Products Sandra Costigan, Marianna Gaca, ChuanLiu, Kevin McAdam, James J. Murphyand Christopher Proctor British American Tobacco 21

Pierre-Marie GUITTON Next Generation Nicotine Delivery London June, 2017

CORESTA In Vitro Toxicity Testing Sub-Group (IVT SG)

Center for Tobacco Reference Products Update on 1R6F Production and Proficiency Testing Program

Smoke Yields of Tobacco-Specific Nitrosamines in Relation to FTC Tar Level and Cigarette Manufacturer: Analysis of the Massachusetts Benchmark Study

Development and Validation of a Portable Puffing Topography Analyser

Reduced-Risk Products Science Update

The Chemical characterisation of E-device Aerosols

CORESTA RECOMMENDED METHOD NÄ 9

DR. MARIANNA D GACA Manager, Pre-Clinical Assessment R&D, British American Tobacco

S.C. Moldoveanu, A.G. Hudson, A. Harrison. R.J. Reynolds Tobacco Co.

In Vitro Disease Model Development Current Challenges

Characterization of Menthol History and Design of Menthol Cigarettes

Heat-not-Burn Products: Scientific Assessment of Risk Reduction

The concept that not all tobacco and nicotine products

CULTEX RFS. CULTEX Technology an innovation for in vitro cell exposure. about us. products. Kazuo Kanazawa. Inhalation Toxicity Testing

Assessment of the Tobacco Heating System (THS) 2.2, A Candidate Modified Risk Tobacco Product: From Concept to Early Clinical Data

Chromatographic Profiling as a Tool in the Comparison and Evaluation of Complex Mixtures

Reduced Risk Review March Keith Lenghaus

The adverse health effects associated with traditional

Global E-Cigarette Market- Industry Analysis & Outlook ( )

THE INFLUENCE OF CIGARETTE FILTER DESIGN ON THE YIELD AND COMPOSITION OF CIGARETTE SMOKE

Routine Analytical Chemistry Sub-Group Report Berlin 2016

COMPARISON OF RESULTS FROM THREE TECHNIQUES FOR THE ESTIMATION OF E-LIQUID ph-values

Contribution To Standards Development For Next Generation Products. Dr Nils ROSE

CORESTA Recommended Method No. 85

What is combustion and why is the absence of combustion important for heat not burn products

Modelling the effects of user exposure to harmful emissions across the spectrum of nicotine delivery

Cigarette Smoke Generator

Contribution To Standards Development For Next Generation Products. Eduardo BEREA Alternative Ingredients ENDS 2018 London 4-5 June 2018

Effect of Sugars on Selected Toxicant Yields in e-cigarettes

Technical Report. Determination of Nitrate in Smokeless Tobacco Products by Continuous Flow Analysis

CORESTA Recommended Method No. 84

Safety/risk assessment of electronic cigarettes

UK E-Cigarette Summit Relative risks of cancer posed by combustible and vapourising forms of nicotine delivery: Evidence from chemical exposures

Assessing the impact of Ploom TECH use on indoor air quality (IAQ)

Smoking Puff Ratio of Cigarette and Its Determination Method

Variability of NNN in Tobacco and NNN Levels in Smokeless Tobacco Products

Cardiovascular effects of nicotine vs. cigarette smoke

GC-MS analysis of e-liquids taken. from e-cigarettes and e-liquids (e-juice) before use in e-cigarettes

The importance of offering adult smokers a portfolio of potentially less harmful products

Aerosol Characterisation of e-cigarettes. Ross Cabot, Anna Koc, Caner U. Yurteri & John McAughey

Air Quality assessment during indoor use of the Tobacco Heating System 2.2

Nicotine delivery from e-cigarettes part I: study designs for two pharmacokinetic studies.

METHOD DEVELOPMENT AND VALIDATION: QUANTIFICATION OF METALS IN LIQUIDS AND AEROSOL OF E-CIGARETTES

Nicotine Pharmacokinetics: Comparison of a cigarette, loose snus, pouched snus and nicotine gum

Tobacco Heating System 2.2, A Candidate Modified Risk Tobacco Product: Cardiovascular Disease Risk Assessment

Regulatory Support for Tobacco Products. Feeling daunted by the regulatory process for tobacco products? Don t worry Battelle can help.

Routine Analytical Chemistry Sub-Group. Technical Report

Advanced in vitro exposure systems VITROCELL VC 1 SMOKING MACHINE

Data Sheet. CD28:B7-2[Biotinylated] Inhibitor Screening Assay Kit Catalog # Size: 96 reactions

Dynamic properties of exhaled e-cigarette aerosol vs. conventional cigarette smoke

RNA-SEQ based toxicogenomics comparison of airway cells exposed to Vype TM epen vapour and cigarette smoke.

Development and validation of a device for measuring puffing topography of e-cigarette users

Progress of the validation of analytical chemical methods for testing and measuring cigarette contents and emissions

Controlling cell-based bioassay performance through controlled preparation of bioassayready

Water pipe tobacco smoking from the first idea to an International Standard

Product Standards for Reducing Nicotine in Cigarettes

Technical Report. CORESTA Reference Products

Approaches for the design of reduced toxicant emission cigarettes

Analysis of short chain organic acids in tobacco and in some flavored e-liquids

Matt S. Melvin, Karen C. Avery, Jason W. Flora, Karl A. Wagner. Altria Client Services LLC l Regulatory Sciences 12Oct2016 Final 1

Genotoxic and inflammatory responses of human bronchial epithelial cells to diesel and biodiesel exhaust.

In Vitro Exposure Systems and Dosimetry Assessment Tools for Inhaled Tobacco Products. April 4-6, 2016 Bethesda, MD

E-Cigarette Product Regulation and Standardisation

Toxicological sciences in Beitraege zur Tabakforschung International (BTFI) during the last 55 years

FEATURES AND PERFORMANCE OF THE HPP SMOKING MACHINE. Dritan Xhillari

HL-60 ATP assay for predicting rat oral toxicity study

2015 Report 05 October 2015 Jeju, South Korea

CORESTA RECOMMENDED METHOD N 25

Assessment of cigarette smoke particle deposition within the Vitrocell W exposure module using quartz crystal microbalances

Variation in Smoke Toxicant Yields from Selected Cigarettes

Smoke Science / Product Technology Abstracts 1

Nicotine Reduction Workshop Role of nicotine in smoking behaviour

CORESTA Recommended Methods with history and correspondence with ISO Standards

Commercial Ave., Northbrook, IL phone: (844)

E-Vapour (EVAP) Sub-Group 2017 Report. Kitzbühel, Austria October 10, 2017

A proposed bridging approach for the assessment of novel tobacco products

Investigation on the Controlling Matters Variation in Cigarette Smoke

Application of dosimetry tools for the assessment of e cigarette aerosol and cigarette smoke generated on two different in vitro exposure systems

I n 1996, the RJ Reynolds Tobacco Company (RJR) began test

Data Sheet. PCSK9[Biotinylated]-LDLR Binding Assay Kit Catalog # 72002

PROCEDURE FOR GENERATION AND TESTING OF MAINSTREAM TOBACCO HEATING SYSTEM (THS or IQOS) AEROSOL USING A LINEAR SMOKING MACHINE

INTERNATIONAL STANDARD

Technical Report. Chemical and physical performance of a filter for cigarette smoke. (patents n. BO2014A )

Definition of Drug. an article (other than food) intended to affect the structure or any function of the body. Sections 201 (g)(1)(c)

Changes in TSNA contents during tobacco storage and the effect of temperature and nitrate level on TSNA formation

DEVELOPMENT OF A TECHNIQUE FOR THE DETERMINATION OF ph-values OF AEROSOLS GENERATED BY E-CIGARETTES

GLOBAL TOBACCO REGULATION OVERVIEW IVAN GENOV RESEARCH ANALYST 31 MAY 2018

Physical and chemical properties of cigarette, heated tobacco and e-cigarette aerosols

Exposure Implications of Electronic Cigarette Surface Contamination

V2 NOTEBOOK-CIG AND/OR V2 POWER-CIG

CORESTA RECOMMENDED METHOD N 8

Transcription:

CORESTA In vitro Toxicology Task Force In vitro exposure of cells to Smoke at the Air Liquid Interface Following the initial objective of the taskforce: To prepare a report to cover the rationale and strategy for conducting in vitro testing of tobacco smoke To identify key procedures based upon internationally recognised guidelines, adapted to accommodate the unique properties of tobacco smoke The taskforce objectives were widened to conduct a preliminary interlaboratory study to compare the whole smoke exposure systems under development in a number of laboratories of task force members. Task force members agreed to evaluate the cytotoxicity, as assessed by neutral red technique, following exposure to the smoke from a range of reference cigarettes. Specifically, laboratories were asked to provide a measure of the contribution of vapour and particulate phases to the cytotoxicity of smoke. Consequently, this report provides a description of the range of systems used in the experimentation and the data produced following measurement of the reference cigarettes used. Experimental Cigarettes Kentucky reference cigarette 2R4F R39 a US grown single grade burley tobacco R31 a Brazilian grown single grade flue cured tobacco R311 a 5:5 blend of the tobaccos included in R39 and R31 Table 1. Average smoke chemistries from participating laboratories (mg cig -1 ) Cigarette TPM mg cig -1 Nicotine mg cig -1 Water mg cig -1 NFDPM mg cig -1 Puffs R39 Burley 24.98 ± 1.59 R31 27.79 FC ±1.71 R311 26.35 FC:Burley ± 1.31 2R4F 1.84 ±.72 2.71 ±.19 2.82 ±.9 2.83 ±.18.79 ±.5 3.63 ± 1.17 3.58 ±1.26 3.43 ± 1.5 1.8 ±.41 18.66 ± 1.52 21.4 ±1.33 2.1 ± 1.15 8.97 ±.56 8.75 9.93 ±.39 9.97 ±.14 8.76 ±.41 1

Laboratories Participating laboratories consisted of: Altadis Fleury-les-Aubrais France Battelle Richland USA British American Tobacco Southampton UK Imperial Tobacco UK Hamburg Germany Japan Tobacco Tokyo Japan Labstat International Kitchener Canada R.J.Reynolds Winston Salem USA Bioassay Endpoints All laboratories measured the neutral red (NR) cytotoxicity of the cell cultures using the technique described by the US National Institute of Environmental health Sciences (1). In summary, the cytotoxicity of the smoke or test material is assessed on the basis of the concentration of test material that results in a 5% inhibition of cell viability as assessed by the neutral red uptake. The lower the concentration that results in a 5% reduction the more cytotoxic the material. Altadis Results The Altadis laboratory used the Cultex (2) air liquid interface exposure system. In summary, for the smoke exposure, cells on porous membranes are brought to the air liquid interface with growth medium underneath and exposed to smoke on the upper surface. A549 cells were exposed for 4 minutes to a range of smoke dilutions, returned to growth medium followed by a recovery period of 2 hours after which NR cytotoxicity was measured. 3 independent experiments were conducted and the cytotoxicity calculated giving 5% reduction computed for each reference cigarette tested Fig. 1. The smoke generated from the products were ranked, most cytotoxic R311 (1:1 mixture FC:Burley) > R31 (FC) > R39 (Burley) > 2R4F. However, none of the differences were significant (Fig. 2) 2

Figure 1. Altadis: A549 Viability versus smoke dilution factor 39 31 311 2R4F 8 7 6 % Viability 5 4 3 2 1 6.77 4.81 3.88 2.92 Smoke Dilution factor Figure 2. Altadis: Newman-Keuls multiple comparison of smoke responses, most cytotoxic was R311 (1:1 mixture FC:Burley) > R31 (FC) > R39 (Burley) > 2R4F. However, none of the differences were significant Moyennes et intervalles à 95,% LSD 59 _ viabilité 56 53 5 47 44 2R4F 39 31 311 Terme 3

Battelle The Battelle smoking system consists of BALB/c 3T3 cells maintained in conventional culture flasks on a temperature controlled rocker platform (Fig 3). An AMESA smoke engine was used to supply diluted smoke at a flow rate of 315 ml min -1 and the platform operated at 1 oscilations per hour. 4 concentrations per experiments were used and 3 cultures per smoke concentration. Cells were exposed for 1 hour and assayed for cytotoxicity 24 hours after smoke exposure. Figure 3. Diagramatic of whole smoke exposure system. Smoke In Smoke out 11º 11º The Inhibitory concentrations of smoke or vapour phase equivalents resulting in a 5% inhibition of cell viability are illustrated in table 2. The data were assessed as a cytotoxic ranking of 2R4F > R31 FC > R39 Burley with a contribution of 7 to 9 % from the vapour phase components. 4

Table 2. Battelle: Inhibitory concentrations resulting in a 5% inhibition of cell viability (µg Litre -1 wet TPM or equivalents) Cigarette Exp. 1 Exp. 2 Mean 2R4F Smoke 3.1 31.6 3.9 Vapour 38.5 4. 39.3 R39 Burley 9.5 9.8 9.7 Smoke R39 Burley 88.9 99.2 94.1 Vapour R31 FC Smoke 57.4 58.6 58. R31 FC Vapour 72.4 72. 72.2 British American Tobacco The BAT system is described in reference 3. Figure 4. BAT whole smoke exposure chambers Diluted smoke is generated by a Borgwaldt RM2S smoking engine and cells on porous membranes are exposed from the upper surface as illustrated in figure 4. whilst at the same time supplied from below with tissue culture media. A human lung epithelial cell line H292 was exposed for 3 minutes and neutral red cytotoxicity measured 2 hours after exposure to smoke. The data is from 3 independent experiments and the smoke concentration is recorded as a dilution factor resulting in a 5% inhibition of cell viability, larger numbers indicate a more cytotoxic smoke. 5

The cytotoxicities of the smokes were ranked as illustrated in table 3. Flue cured was most cytotoxic followed by 2R4F, and burley was least cytotoxic. However, these differences were not statistically significant when evaluated by t-testing. Table 3. BAT - Smoke dilutions producing 5% inhibition of cell viability Cigarette Dilution to give Inhibitory concentration 5% R31 Flue Cured 18 2R4F 94 R39 Burley 87 For the vapour phase experiments, a Cambridge filter was included between the cigarette and the exposure chamber, the data is illustrated in figure 5. The shift in the dose response curve for vapour phase in comparison to whole smoke was calculated with the vapour phase accounting for 8% - 9% of the response. Figure 5. Responses for cigarettes with either % or 7% ventilation illustrating the contribution from both whole smoke or vapour phase. Imperial Tobacco UK (IT) The IT system uses a standard 96 well cell culture plate with 35 ml smoke injected into each of the 96 wells Fig 6. A Hep-G2 human liver cell line is used, growth medium is poured off the plates and smoke passed puff by puff over the cells for 3 minutes. The cells are then returned to culture under growth medium for a further 65 hours and then assayed for neutral red cytotoxicity. 6

Figure 6. Imperial Tobacco : Fresh smoke exposure system (whole smoke or vapour phase) Smoke In + Out 96 well plate Cells + Overlying media The puff specific concentrations resulting in a 5% inhibition in cell viability are illustrated in Figure 7, indicating most cytotoxic R31 (FC) >R311 (1:1) >R39 Burley >2R4F. When a Cambridge filter was placed between the cigarette and the exposure system, there is a 1% - 25% contribution from the vapour phase to the cytotoxicity of smoke, the remainder coming from the particulate phase (Figure 8). Figure 7. Imperial Tobacco Relative cytotoxicities of smoke from the reference cigarettes expressed as number of puffs reducing cell viability by 5% Cig. Sp. EC5 2 17,5 15 cig. equiv. [%] 12,5 1 7,5 5 2,5 R 3 9 R 3 1 1 R 3 1 2 R 4 F 8 Tests 3 tests at optimum dose responses 7

Figure 8. Imperial Tobacco. Proportion of the cytotoxic response contributed by vapour phase and particulate phase components of tobacco smoke. 1% 75% 5% 25% Cigarette % R39 R31 R311 2R4F Burley Flue cured 1:1 Blend 2R4F % of Vapour Phase toxicity of Whole Smoke toxicity 12.5 15.7 16. 26.6 ISO-TPM [mg/cig] 25.5 29.2 26.9 11.9 mg / Cigarette 895 944 956 16 Puffs / Cig. 7.3 8.5 8.4 7.7 Japan Tobacco (JT) The JT group used the CULTEX TM air liquid interface exposure system with A549 cells maintained on Transwell TM membranes. The cells were subject to 2 to 3 minute exposures of diluted smoke from a 35ml puff separated by 1 minutes then returned to submersion culture for 18 hours before measuring the cytotoxicity by the neutral red accumulation technique. The data for the reference products are set out in Figure 9 and when measured on a per cigarette basis, the cytotoxic ranking was (no statistical computation): R31 (FC) > R39 (Burley) > 2R4F (Table 4) 8

Table 4. Japan Tobacco. Cigarettes giving 5% inhibition of NR cell viability Cigarette Cigarettes giving 5% reduction in NR cytotoxicity R31 Flue cured 1.6 R39 Burley 1.44 2R4F 1.65 Figure 9. Japan Tobacco plots of NR dose responses for the 3 reference cigarettes. Via bility, % of co ntrol 12 1 8 6 4 2 R39 R31 2R4F 1 2 3 4 Cigarettes The response from the vapour phase vs whole smoke is illustrated in Figure 1, with an estimation of a 66 76% contribution of vapour phase to the cytotoxicity of the whole smoke. Figure 1. Japan Tobacco. Cytotoxicities of whole smoke versus smoke vapour phase (GVP) V ia bility, % of c o ntro l 12 1 8 6 4 2 1 2 3 4 Cigarettes Whole Smoke GVP V ia b ility, % o f c o ntro l 12 1 8 6 4 2 Whole Smoke GVP 1 2 3 4 Cigarettes 9

Labstat International Labstat assessed the cytotoxicities of the smoke from the reference cigarettes using the methodology set out in the Health Canada guidelines (4). In summary, using an ISO smoking regimen, particulate matter (TPM) is collected on Cambridge filter pads whilst simultaneously collecting the gas vapour phase in phosphate buffered saline. TPM is then extracted into dimethyl sulphoxide (DMSO) (1mg TPM ml -1 ) whilst the gas vapour phase is adjusted to give a 1 mg ml -1 TPM equivalent in phosphate buffered saline. For the whole smoke solution the DMSO and gas vapour phase solution are combined at a 1:1 ratio. A CHO cell line was exposed to a concentration range of smoke solutions for 24 hours followed by the neutral red cytotoxicity procedure. Note there is no recovery phase between the treatment with smoke solution and the measurement of cytotoxicity. The plot of smoke concentrations inhibiting cell viability by 5% are illustrated in Figure 11. Figure 11. Labstat International cytotoxicities of test products 7 Particulate Phase Gas/Vapour Phase Whole Smoke 6 6 IC 5 µg ml -1 IC 5 R ang e (µg /ml) 5 4 4 3 2 1 R39 USR39 Burley US Burley R31 Brazil R31 FC Brazi FC R311 Burley R311 + FC Burley + FC 2R4F KR 2R4F 1

These data were subject to analysis of variance and student-newman-keul Multiple Comparison tests which indicated that the whole smoke from 2R4F was significantly more cytotoxic than that from the other reference products which could not be differentiated in activity. R. J. Reynolds The system used is in principle the same as that used by the Battelle group a rocking platform maintained at 37 C on which cell culture flasks are placed and supplied with diluted smoke (Bombick, 1997).CHO cells were used as the target and experiments conducted on 3 separate occasions. The data (Fig. 12) were log transformed and statistical analysis carried out using a pairwise T- test from ANOVA, with Bonferroni adjustment. The product ranked as most cytotoxic was R31 (FC) > R311 (1:1 mix) > R39 Burley > 2R4F. The difference between the R31 FC and R39 burley was statistically significant, whilst the 2R4F smoke was significantly less cytotoxic that the smoke from the other reference cigarettes. Figure 12. R. J. Reynolds. Data expressed per mg wet TPM and per cigarette. 1 9 RJR Whole Smoke: per-cigarette basis 1 9 RJR Whole Smoke---per mg basis Percent of Control (+/- S.E.) 8 7 6 5 4 3 US Burley (R39) Flue cured (R31) 1:1 mix (R311) 2R4F Percent of Control (+/- S.E.) 8 7 6 5 4 3 2 1 2 1 US Burley (R39) Flue cured (R31) 1:1 mix (R311) 2R4F 1 2 3 4 5 6 7 8 9 1 11 12.2.4.6.8.1.12.14.16.18.2 Cigarettes/M 3 mg WTPM/L 11

Summary and Conclusions All laboratories were able to measure the whole smoke cytotoxicity of the reference cigarettes provided. The differences in the cytotoxicity of the reference products tested were minimal with occasional significant differences between the smoke cytotoxicities. All laboratories conducting exposure at the air liquid interface, ranked the smoke from flue cure cigarettes as marginally more cytotoxic than the smoke from the all burley cigarette For both exposure on Transwell TM membranes and in cell culture flasks the vapour phase contribution to whole smoke cytotoxicity was in the region of 7% to 8%. The cell line used to perform the experiments did not have a significant effect on the data patterns produced nor did minor protocol variants. Overall, the whole smoke exposure systems produce remarkably similar data sets and form a platform for the Industry to be able to investigate the in vitro toxicology of vapour phase of tobacco smoke. Table 5. Summary table of basic parameters of the exposure systems and cytotoxic rankings of the smokes. Group Cell Line Exp. Time (min) Post exp (hrs) Comparison basis Rank Cytotoxicity Altadis A549 4 2 Cigarette 1:1 FC USB 2R4F % VP BAT H292 3 2 Cigarette FC 2R4F USB 8-9 ITL Hep-G-2 3 65 Cigarette FC > 1:1 > USB > 2R4F 1-25 JT A549 2-3 2 Cigarette FC > USB > 2R4F 66-76 Labstat CHO 24 hr -- TPM + GVP 2R4F > FC = USB = 1:1 RJR CHO 6 24 TPM Cigarette 2R4F FC = 1:1 > USB FC = 1:1 > USB > 2R4F Battelle 3T3 6 24 TPM 2R4F > FC > USB 7-9 12

References 1. US NIH publication No: 7-4519 In vitro cytotoxicity test method for estimating starting doses for acute oral systemic toxicity tests. http://ntpapps.niehs.nih.gov/iccvampb/searchdoc.cfm 2. Aufderheide M., Knebel J.W., Ritter D. An improved in vitro model for testing the pulmonary toxicity of complex mixtures such as cigarette smoke. Exp. Toxicol. Pathol. 55 (1) 51-57, 23 3. Phillips J., Kluss B., Richter A. and E. D. Massey Exposure of bronchial epithelial cells to whole cigarette smoke: assessment of cellular responses. ATLA 33, 239-248, 25. 4. Health Canada Official method T-52 Neutral Red Uptake Assay for Mainstream Tobacco Smoke 5. Bombick D.W., Ayres P.H. and D.J. Doolittle. Cytotoxicity Assessment of whole smoke and vapor phase of mainstream and sidestream cigarette smoke from three Kentucky Reference cigarettes. Tox Methods, 7: 177-19, 1997. 13